Hims And Hers Steps Back While Novo Nordisk Steps Up

Hims & Hers came out swinging with a $49 compounded semaglutide pill plan, then backed away fast—canceling the launch over the weekend after legal threats from Novo Nordisk and rising U.S. FDA pressure around compounded GLP-1 products. Investors immediately read the room - Novo Nordisk jumped more than 8%, while Hims fell about 15% on Feb. 9 before the market opened.

The FDA had already signaled tougher action days earlier — restricting access to GLP-1 ingredients used in non-approved compounded drugs and referring Hims & Hers to the Department of Justice for potential federal-law violations. Hims & Hers is finding out fast that the era of “move fast and make a compound” is meeting the era of “show us your homework”.

Lilly shares rose alongside Novo on the news — because anything that reduces low-cost, copycat pressure on GLP-1 demand tends to help the large, branded incumbents - especially when they are perceived to be shielded from the pressures affecting smaller competitors. The market is making clear that regulatory durability matters as much as marketing creativity. It's impossible to tell when Hims & Hers will recover from this setback, and some analysts have maintained a cautious outlook, with many holding a "hold" rating. Hims & Hers plans to announce its full-year 2025 results on February 23, 2026, and we'll see where that takes it. For now, after legal threats and FDA scrutiny - everyone should note this isn’t a loophole market anymore.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726